Research programme: antibacterials and antivirals - Galapagos/GlaxoSmithKline

Drug Profile

Research programme: antibacterials and antivirals - Galapagos/GlaxoSmithKline

Latest Information Update: 09 Feb 2011

Price : $50

At a glance

  • Originator Galapagos NV
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Bacterial infections; Viral infections

Most Recent Events

  • 09 Feb 2011 Galapagos receives grant from the Innovation by Science and Technology for antivirals development
  • 19 Jan 2009 Galapagos & GSK expand their alliance
  • 10 Dec 2007 Early research in Bacterial infections in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top